New drug bimekizumab shows promise for psoriasis in early trial
NCT ID NCT03025542
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizumab could be a safe and effective treatment for this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimekizumab
What this could lead to
If successful, this could lead to a new treatment option for people with moderate to severe plaque psoriasis, helping to clear skin and reduce symptoms.
What could go wrong
This was a small, early-phase study (Phase 2) with only 49 participants. Larger trials are needed to confirm safety and effectiveness. Some participants may still experience side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ps0016 101
Melbourne, Australia
-
Ps0016 102
Kogarah, Australia
-
Ps0016 104
Woolloongabba, Australia
-
Ps0016 201
Ajax, Canada
-
Ps0016 202
Windsor, Canada
-
Ps0016 203
London, Canada
-
Ps0016 501
Chisinau, Moldova
-
Ps0016 704
Bexley, Ohio, United States